CLEE011X2102: A Phase I Multi-Center, Open-Label Study of LEE011 in Patients with Malignant Rhabdoid Tumors and Neuroblastoma.

Why are we doing this research?

The primary purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) in pediatric patients and to delineate a clinical dose to be used in future studies. This study will also assess the safety, tolerability, PK and preliminary evidence of antitumor activity of LEE011 in patients with MRT or neuroblastoma.

Who can participate?

Patients between the ages of 1 and 21 years with malignant rhabdoid tumors and neuroblastoma are eligible for this study.


  • From 1 to 21 years old


  • Female
  • Male


For more information contact:

Cincinnati Children’s Hospital Medical Center
Division of Hematology/Oncology
3333 Burnet Ave., Cincinnati, OH 45229-3039
Phone: 513-636-2799